Article
Discovery of M2 channel blockers targeting the drug-resistant double mutants M2-S31N/L26I and M2-S31N/V27A from the influenza A viruses.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences - 1 Jan 2020
Musharrafieh Rami, Ma Chunlong, Wang Jun
Abstract excerpt
Influenza virus infections are a persistent threat to human health due to seasonal outbreaks and sporadic pandemics. Amantadine and rimantadine are FDA-approved influenza antiviral drugs and work by inhibiting the viral M2 proton channel. However, the therapeutic potential for the antiviral amantadine/rimantadine was curtailed by the emergence of drug-resistant mutations in its target protein M2. In this study,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
